安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Efficacy and safety of continuous every-2-week dosing of ixekizumab . . .
Background: Ixekizumab is an interleukin-17A antagonist approved for treatment of moderate-to-severe plaque psoriasis with a recommended 160-mg starting dose, then 80 mg every 2 weeks (Q2W) to week 12, and every 4 weeks (Q4W) thereafter Objective: To evaluate continuous Q2W dosing over 52 weeks
- Dosing Schedule | PSA, AS nr-axSpA | Taltz (ixekizumab)
After the starting dose of two 80 mg injections, 1 injection every 2 weeks for 3 months (12 weeks), then once a month * thereafter If patients forget to take their Taltz dose, instruct them to inject a dose as soon as they remember; then, to take their next dose at the regularly scheduled time
- Efficacy and safety of continuous every‐2‐week dosing of ixekizumab . . .
Ixekizumab is an interleukin-17A antagonist approved for treatment of moderate-to-severe plaque psoriasis with a recommended 160-mg starting dose, then 80 mg every 2 weeks (Q2W) to week 12, and every 4 weeks (Q4W) thereafter To evaluate continuous Q2W dosing over 52 weeks
- Ixekizumab: Uses, Dosage, Side Effects, Warnings - Drugs. com
160 mg (two 80 mg injections) subcutaneously at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks Use: For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
- Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe . . .
This report focuses on data from patients who received the approved regimen (an initial dose of 160 mg, 80 mg ixekizumab every 2 weeks up through week 12 and 80 mg ixekizumab every 4 weeks thereafter)
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the
- Continuous dosing versus interrupted therapy with ixekizumab: an . . .
Patients were randomized to placebo (PBO), IXE every 4 (Q4W) or IXE every 2 weeks (Q2W) for 12 weeks Patients with a static Physician's Global Assessment (sPGA) 0, 1 at Week 12 were rerandomized to IXEQ 4W, IXE every 12 weeks (not presented) or PBO
- Extended dosing intervals of ixekizumab for psoriasis: A single-center . . .
Herein, we used our results using a modified dose regimen of IXE, consisting of 160 mg of IXE as an induction dose, followed by 80 mg at week 2, 4, and 8, and every 8 weeks thereafter, for the treatment of 39 psoriatic patients at our department
|
|
|